antiviral | Medical XPRT

News

Report On Activities For The Quarter Ended 31 March 2022

During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including: Confirmed and extended previous findings on the effectiveness of Biotron's lead antiviral drug BIT225 ...

Equipment & Solutions

Showcase

Epclusa Hepatitis C Treatment

Sofosbuvir 400 mg/velpatasvir 100 mg. Epclusa® is indicated for the treatment of adult and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.